Your browser is no longer supported. Please, upgrade your browser.
Curis, Inc.
Index- P/E- EPS (ttm)-0.50 Insider Own0.10% Shs Outstand91.51M Perf Week4.04%
Market Cap704.79M Forward P/E- EPS next Y-0.43 Insider Trans-5.54% Shs Float85.83M Perf Month-1.71%
Income-30.10M PEG- EPS next Q-0.11 Inst Own90.50% Short Float18.64% Perf Quarter-29.53%
Sales10.30M P/S68.43 EPS this Y36.60% Inst Trans2.97% Short Ratio4.20 Perf Half Y-31.84%
Book/sh1.33 P/B5.62 EPS next Y4.40% ROA-24.80% Target Price- Perf Year474.62%
Cash/sh1.66 P/C4.51 EPS next 5Y- ROE-62.20% 52W Range0.90 - 17.40 Perf YTD-8.79%
Dividend- P/FCF- EPS past 5Y23.80% ROI-18.90% 52W High-57.07% Beta2.93
Dividend %- Quick Ratio23.20 Sales past 5Y6.60% Gross Margin95.00% 52W Low730.00% ATR0.41
Employees28 Current Ratio23.20 Sales Q/Q-18.50% Oper. Margin- RSI (14)39.17 Volatility6.03% 5.71%
OptionableYes Debt/Eq0.01 EPS Q/Q61.50% Profit Margin- Rel Volume0.33 Prev Close7.70
ShortableYes LT Debt/Eq0.00 EarningsMay 12 AMC Payout- Avg Volume3.81M Price7.47
Recom2.00 SMA20-1.12% SMA50-28.06% SMA200-9.47% Volume1,260,858 Change-2.99%
Mar-25-21Initiated B. Riley Securities Buy $19
Jul-29-20Initiated Laidlaw Buy $5
Jul-17-20Initiated Cantor Fitzgerald Overweight $4
Oct-24-17Initiated Guggenheim Buy $7
Mar-02-16Initiated Sun Trust Rbsn Humphrey Buy $3
Nov-09-15Reiterated ROTH Capital Buy $6 → $5
Aug-11-15Initiated FBR Capital Outperform $6
Jan-22-15Reiterated Oppenheimer Outperform $3 → $5
Jan-21-15Reiterated ROTH Capital Buy $10 → $6
May-09-14Reiterated Oppenheimer Outperform $4.50 → $3
Oct-02-13Initiated Robert W. Baird Outperform $7
Sep-30-13Initiated Chardan Capital Markets Buy $6
Nov-14-12Initiated Stifel Nicolaus Hold
Jan-31-12Reiterated Summer Street Research Buy $5 → $7
Jan-31-12Reiterated Brean Murray Buy $5 → $6
Dec-09-11Initiated Oppenheimer Outperform $6
Oct-06-11Initiated Summer Street Research Buy $5
Sep-22-11Initiated MLV Capital Buy $8.50
Mar-21-11Reiterated Brean Murray Buy $4 → $5
Feb-26-10Reiterated Roth Capital Buy $5 → $4.50
Jul-07-21 04:01PM  
Jul-06-21 12:52PM  
Jun-28-21 05:17PM  
Jun-26-21 05:50PM  
Jun-25-21 08:00AM  
Jun-22-21 06:35PM  
Jun-21-21 05:37PM  
Jun-20-21 01:53PM  
Jun-17-21 06:42PM  
Jun-16-21 04:50AM  
Jun-14-21 03:26AM  
Jun-11-21 05:54PM  
Jun-08-21 03:16PM  
Jun-04-21 08:00AM  
Jun-01-21 08:00AM  
May-25-21 08:01AM  
May-20-21 09:05AM  
May-13-21 06:42PM  
May-12-21 04:01PM  
May-05-21 08:00AM  
May-04-21 03:00PM  
Apr-19-21 08:00AM  
Apr-07-21 04:01PM  
Apr-06-21 08:00AM  
Mar-25-21 10:17AM  
Mar-19-21 01:42AM  
Mar-17-21 09:05AM  
Mar-16-21 09:00PM  
Mar-10-21 04:30PM  
Mar-09-21 08:00AM  
Feb-19-21 08:00AM  
Feb-17-21 01:03AM  
Feb-09-21 08:00AM  
Feb-02-21 08:00AM  
Jan-14-21 08:00AM  
Jan-08-21 04:01PM  
Jan-05-21 08:00AM  
Dec-22-20 04:05PM  
Dec-14-20 08:00AM  
Dec-11-20 08:44AM  
Dec-10-20 09:52PM  
Dec-09-20 03:02PM  
Dec-08-20 04:13PM  
Dec-07-20 01:30PM  
Dec-02-20 08:40AM  
Nov-24-20 09:51AM  
Nov-10-20 04:54PM  
Nov-04-20 01:29PM  
Nov-02-20 04:01PM  
Oct-21-20 08:00AM  
Oct-14-20 05:01PM  
Sep-18-20 07:05AM  
Sep-10-20 04:01PM  
Aug-04-20 04:01PM  
Jul-28-20 08:00AM  
Jul-07-20 08:00AM  
Jun-21-20 10:09PM  
Jun-11-20 09:25AM  
Jun-10-20 08:00AM  
Jun-04-20 07:24PM  
Jun-03-20 09:33AM  
May-12-20 04:01PM  
May-05-20 08:00AM  
Apr-07-20 08:00AM  
Apr-03-20 04:01PM  
Mar-19-20 04:01PM  
Mar-12-20 08:00AM  
Feb-27-20 08:00AM  
Feb-06-20 08:30AM  
Jan-13-20 08:00AM  
Jan-08-20 04:31PM  
Jan-07-20 08:05AM  
Dec-23-19 06:24PM  
Dec-22-19 08:33AM  
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation that is in Phase Ia/Ib clinical trial in patients with solid tumors. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. The company was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dentzer James EPresident & CEOJan 26Sale10.593,09432,75867,268Jan 26 06:20 PM
Dentzer James EPresident & CEOJan 25Sale10.962,28325,02270,362Jan 26 06:20 PM